LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 108 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $52,403,228 | 3.69% |
| Raffles Associates | 1,536,946 | $2,305,419 | 3.14% |
| Defender Capital, LLC. | 5,136,085 | $7,704,128 | 2.69% |
| Prescott General Partners LLC | 1,851,851 | $2,777,777 | 0.22% |
| DAFNA Capital Management LLC | 140,000 | $210,000 | 0.06% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $67,500 | 0.05% |
| CTC Capital Management, LLC | 14,100 | $21,150 | 0.04% |
| Diametric Capital, LP | 50,875 | $76,313 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $1,172,649 | 0.03% |
| One68 Global Capital, LLC | 13,377 | $20,066 | 0.03% |